Merz Partners with DiaGenic on Alzheimer's Biomarkers | GenomeWeb

NEW YORK (GenomeWeb News) – DiaGenic today said that it has licensed biomarkers for mild cognitive impairment to drug firm Merz Pharmaceuticals, which will use the biomarkers for recruiting patients for Alzheimer's disease drug trials.

Frankfurt am Main, Germany-based Merz also has an option to license non-exclusive rights to further biomarkers, under terms of the agreement. Financial details and further terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."